ReviewHematology. American Society of Hematology. Education Program2017
Evolving treatment paradigms in sickle cell disease.
Review in Hematology. American Society of Hematology. Education Program, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 23 citations in OpenAlex.
- Double-blind, randomized, multicenter phase 2 study of SC411 in children with sickle cell disease (SCOT trial).Blood advances · 2018Trial
- Global Prevalence of Alloimmunization in Adults with Sickle Cell Disease Receiving Red Blood Cell Transfusions: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2026Review
- Laboratory predictors of sickle cell disease severity: a cross-sectional study.Journal of medicine and life · 2024Article
- Article
- Mitochondria: Emerging Consequential in Sickle Cell Disease.Journal of clinical medicine · 2023Review
- Predictors of Intensive Care Admission Among Adult Patients with Sickle Cell Disease in Eastern Province of Saudi Arabia.Journal of blood medicine · 2023Article
- Sickle Cell Disease Knowledge and Reproductive Decisions: A Saudi Cross-Sectional Study.Patient preference and adherence · 2023Article
- Development and clinical translation ofComputational and structural biotechnology journal · 2022Review
- The Worst Things in Life are Free: The Role of Free Heme in Sickle Cell Disease.Frontiers in immunology · 2020Review
- Review
- Emerging disease-modifying therapies for sickle cell disease.Haematologica · 2019Review
- Substitutions in the β subunits of sickle-cell hemoglobin improve oxidative stability and increase the delay time of sickle-cell fiber formation.The Journal of biological chemistry · 2019Article
- New insights into the pathophysiology and development of novel therapies for sickle cell disease.Hematology. American Society of Hematology. Education Program · 2018Review
- Hemoglobin oxidation-dependent reactions promote interactions with band 3 and oxidative changes in sickle cell-derived microparticles.JCI insight · 2018Article
- Potential role of LSD1 inhibitors in the treatment of sickle cell disease: a review of preclinical animal model data.American journal of physiology. Regulatory, integrative and comparative physiology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Sickle cell disease (SCD) is an inheritable hemoglobinopathy characterized by polymerization of hemoglobin S in red blood cells resulting in chronic hemolytic anemia, vaso-occlusive painful crisis, and multiorgan damage. In SCD, an increased reactive oxygen species (ROS) generation occurs both inside the red blood cells and inside the vascular lumen, which augment hemolysis and cellular adhesion. This review discusses the evolving body of literature on the role of ROS in the pathophysiology of SCD as well as some emerging therapeutic approaches to SCD with a focus on the reduction of ROS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.